Head and neck carcinoma research

Nasal submucosal administration of antigen-presenting cells induces effective immunological responses in cancer immunotherapy

Migration and immunological reaction after the administration of ╬▒GalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer

Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.

Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer

 

 

 

 

 

 

 

New 7DW8-5 glycolipid

7DW8-5

Now available 7DW8-5 glycolipid derivative of Alpha-GalCer for human and mice iNKT immunoresearch

 

Meet Funakoshi Company
at the following meetings:

NIH Festival
Bethesda, Maryland
September 14-15, 2017

The 76th Annual Meeting of the Japanese Cancer Association
Yokohama, Japan
September 28-30, 2017

ASCB
Philadelphia, PA
December 2-6, 2017